非小细胞肺癌中DLL4蛋白的表达及其临床意义

Expression of DLL4 in NSCLC and and its clinical significance

目的探讨DLL4蛋白在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其与临床病理参数、患者生存预后之间的关系。方法采用免疫组化法检测DLL4蛋白在89例NSCLC组织和癌旁正常肺组织中的表达。结果 89例NSCLC中,52例DLL4蛋白高表达,高表达的阳性率为58.4%,明显高于癌旁正常肺组织,差异具有统计学意义(P<0.05)。此外,DLL4蛋白高表达与TNM分期(P=0.010 78)显著相关。Kaplan-Meier生存分析显示,DLL4蛋白在NSCLC组织中表达水平越高其总生存时间越短。结论 DLL4蛋白高表达与NSCLC进展和不良预后显著相关,因此,DLL4蛋白的表达水平可作为预测NSCLC患者预后的临床指标。

Purpose To assess the expression of DLL4 in non-small cell lung cancer （ NSCLC） patients and to determine its associa-tion with clinicopathological parameters and prognosis. Methods DLL4 expression was evaluated in NSCLC tissues and adjacent non-cancerous normal lung tissues from 89 patients undergoing surgical treatment by immunohistochemistry. Results DLL4 had high ex-pression in 52 of 89 cases of NSCLC （58. 4%）, which was significantly higher than that in adjacent non-cancerous lung tissues （P〈0. 05）. Moreover, DLL4 overexpression was significantly correlated with TNM stage （P=0. 010 78）. Kaplan-Meier survival analysis showed that the overall survival times in patients expressing DLL4 in NSCLC were shorter. Conclusion High level of DLL4 expression is significantly correlated with NSCLC progression and unfavorable prognosis. Thus, DLL4 expression may be used as a clinical param-eter for predictive prognostication of NSCLC patients.